NEO

Neogenomics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.34
-1.12
-2.64%
After Hours: 40.50 -0.84 -2.03% 18:38 10/23 EDT
OPEN
42.47
PREV CLOSE
42.46
HIGH
43.50
LOW
40.65
VOLUME
616.11K
TURNOVER
--
52 WEEK HIGH
44.58
52 WEEK LOW
19.43
MARKET CAP
4.57B
P/E (TTM)
-812.1807
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 4d ago
NeoGenomics (NEO) Looks Good: Stock Adds 5.5% in Session
NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zacks · 10/15 13:00
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14)
Benzinga · 10/15 12:03
The Daily Biotech Pulse: Patent Award For Theratechnologies, Enzo Biochem's Q4, Codiak Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 13)
Benzinga · 10/14 11:53
Hedge Funds Are Piling Into NeoGenomics, Inc. (NEO)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress. […]
Insider Monkey · 10/13 17:31
NeoGenomics expands global footprint in Suzhou, China
NeoGenomics ([[NEO]] -0.6%) plans to open a state-of-the-art research laboratory by 2021 in China in association with the new lab PPD ([[PPD]] +0.1%) is opening in Suzhou.The NeoGenomics laboratory is
Seekingalpha · 10/13 15:14
NeoGenomics Announces Plans to Expand Global Footprint in Pharma Services by Opening Clinical Research Laboratory in Suzhou, China
NeoGenomics continues to build its world-class pharma clinical research capabilities to include servicing Greater China-based clinical trialsFORT MYERS, FL / ACCESSWIRE / October 13, 2020 / NeoGenomics, Inc.
ACCESSWIRE · 10/13 14:00
NeoGenomics Schedules Its Third Quarter Earnings Release for October 27, 2020
MYERS, FL / ACCESSWIRE / October 1, 2020 / NeoGenomics, Inc.
ACCESSWIRE · 10/01 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NEO. Analyze the recent business situations of Neogenomics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NEO stock price target is 42.06 with a high estimate of 46.00 and a low estimate of 39.00.
EPS
Institutional Holdings
Institutions: 268
Institutional Holdings: 93.89M
% Owned: 85.02%
Shares Outstanding: 110.43M
TypeInstitutionsShares
Increased
109
10.55M
New
41
2.84M
Decreased
67
3.76M
Sold Out
23
673.59K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+1.09%
Healthcare Providers & Services
+1.38%
Key Executives
Chairman/Chief Executive Officer/Director
Douglas VanOort
President
George Cardoza
Chief Financial Officer
Kathryn McKenzie
Corporate Executive
Robert Shovlin
Chief Accounting Officer/Controller
Cynthia Dieter
Chief Information Officer
Steven Ross
Chief Compliance Officer
Stephanie Bywater
Vice President
Jennifer Balliet
General Counsel/Secretary
Denise Pedulla
Director of Investor Relations/IR Contact Officer
William Bonello
Other
Douglas Brown
Other
Lawrence Weiss
Lead Director/Independent Director
Lynn Tetrault
Director
Steven Jones
Director
Rachel Stahler
Independent Director
Bruce Crowther
Independent Director
Alison Hannah
Independent Director
Raymond Hipp
Independent Director
Kevin Johnson
Independent Director
Stephen Kanovsky
Independent Director
Michael Kelly
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NEO
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of NeoGenomics, Inc. stock information, including NASDAQ:NEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NEO stock methods without spending real money on the virtual paper trading platform.